Showing results (241-250 of 252) with videos related to

Sort By:
Pageof 26
Journal of Medicinal Chemistry|November 30, 2004
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl groupWilliam Kemnitzer, John Drewe, Songchun Jiang, et al.
World Journal of Gastroenterology|November 8, 2003
Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parametersLun-Gen Lu, Min-De Zeng, Mo-Bin Wan, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positionsWilliam Kemnitzer, Shailaja Kasibhatla, Songchun Jiang, et al.
World Journal of Gastroenterology|May 20, 2005
Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis BPing Liu, Yi-Yang Hu, Cheng Liu, et al.
Cancer Research|April 15, 2010
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activityCheng-Jung Lai, Rudi Bao, Xu Tao, et al.
World Journal of Gastroenterology|December 12, 2003
Relationship between clinical and pathologic findings in patients with chronic liver diseasesLun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 27, 2004
[Oxymatrine in the treatment of chronic hepatitis B for one year: a multicenter random double-blind placebo-controlled trial]Lun-gen Lu, Min-de Zeng, Yi-min Mao, et al.
World Journal of Gastroenterology|October 16, 2004
Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical studyYi-Min Mao, Min-De Zeng, Lun-Gen Lu, et al.
Hepatology International|May 29, 2026
Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trialYu Wang, Huifen Wang, Jun Cheng, et al.
World Journal of Gastroenterology|November 8, 2003
Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trialLun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Pageof 26